TORL Biotherapeutics has raised a $158M Series B funding round to develop cancer therapies.
Goldman Sachs Management was the lead investor.
- TORL
BioTherapeutics is a clinical-stage biopharmaceutical company that aims
to develop antibody-based therapeutics for cancer patients.
- In
addition to Goldman Sachs, other investors that participated in the
round include UC, Bristol Myers Squibb, Deep Track Capital, Vertex
Ventures HC, Moore Strategic Ventures, Cowen Healthcare Investments,
Perceptive Xontogeny Venture Fund, Alexandria Venture Investments, and
OCV Partners.
- The company aims to use the funding to advance:
- TORL-1-23, a clinical-stage solutions ADC targeting Claudin 6,
- TORL-2-307, a clinical-stage solution targeting Claudin 18.2,
- and other novel clinical and preclinical stage programs.
- The company is based in Los Angeles.
